CN101754755A - 促进跨粘膜递送的组合物及方法 - Google Patents

促进跨粘膜递送的组合物及方法 Download PDF

Info

Publication number
CN101754755A
CN101754755A CN200880011979A CN200880011979A CN101754755A CN 101754755 A CN101754755 A CN 101754755A CN 200880011979 A CN200880011979 A CN 200880011979A CN 200880011979 A CN200880011979 A CN 200880011979A CN 101754755 A CN101754755 A CN 101754755A
Authority
CN
China
Prior art keywords
amount
compositions
group
phenylalanine
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011979A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·鲁宾斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Derma Young Ltd
Original Assignee
Derma Young Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Derma Young Ltd filed Critical Derma Young Ltd
Publication of CN101754755A publication Critical patent/CN101754755A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN200880011979A 2007-02-15 2008-02-14 促进跨粘膜递送的组合物及方法 Pending CN101754755A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90134507P 2007-02-15 2007-02-15
US60/901,345 2007-02-15
PCT/IL2008/000192 WO2008099397A2 (en) 2007-02-15 2008-02-14 Compositions and methods for enhancing transmucosal delivery

Publications (1)

Publication Number Publication Date
CN101754755A true CN101754755A (zh) 2010-06-23

Family

ID=39690605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011979A Pending CN101754755A (zh) 2007-02-15 2008-02-14 促进跨粘膜递送的组合物及方法

Country Status (10)

Country Link
US (1) US20100086495A1 (enExample)
EP (1) EP2114384A4 (enExample)
JP (1) JP2010519196A (enExample)
KR (1) KR20090125100A (enExample)
CN (1) CN101754755A (enExample)
AU (1) AU2008215771A1 (enExample)
BR (1) BRPI0807943A2 (enExample)
CA (1) CA2678500A1 (enExample)
WO (1) WO2008099397A2 (enExample)
ZA (1) ZA200905697B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104352461A (zh) * 2013-04-28 2015-02-18 南京海融医药科技有限公司 他达拉非的口服药物制剂
CN111956652A (zh) * 2020-08-21 2020-11-20 重庆康刻尔制药股份有限公司 一种西地那非口腔膜剂药物组合及其制备方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100209419A1 (en) * 2008-08-15 2010-08-19 Rajiv Bhushan Method and formulation for treating adverse biological conditions
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
TR200907338A1 (tr) * 2009-09-28 2011-04-21 Yed�Tepe �N�Vers�Tes� Doğal bileşenler içeren bir film şeridi.
KR101171832B1 (ko) 2009-10-30 2012-08-14 박경식 부작용을 제거한 장기간 복용 차 및 그 조성물
TR201103770A1 (tr) * 2011-04-19 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Nimesulid ve metilsülfonilmetanin topikalfarmasötik bileşimleri.
RU2014148805A (ru) * 2012-05-03 2016-06-20 Раджив Бхушан Лечение воспалительных состояний и улучшение гигиенического состояния полости рта с помощью агентов, связывающих металлы, и метилсульфонилметана в качестве усилителя их транспорта
WO2014024193A1 (en) * 2012-08-07 2014-02-13 Prodel Pharma Ltd. Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients
JP6869637B2 (ja) 2012-12-20 2021-05-12 ビュシャン，ラジブ 抗菌性組成物
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US20160095868A1 (en) * 2013-04-17 2016-04-07 Morris Notelovitz Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
US9855234B2 (en) 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
KR101484481B1 (ko) * 2014-08-07 2015-01-20 주식회사 다림바이오텍 Pde-5 저해제를 포함하는 설하분무제의 제조방법 및 이에 의하여 제조된 설하분무용 조성물
NL2015957B1 (en) * 2015-12-14 2017-06-29 Scala Pharma B V Compositions and methods for inducing beige or brown fat tissue.
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form
JP2023551500A (ja) * 2020-12-04 2023-12-08 イノボバイオロジック， インコーポレイテッド 栄養補助食品組成物のための共融マトリックス
WO2023129171A1 (en) * 2021-12-31 2023-07-06 LIVIONEX, Inc. Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005293A1 (en) * 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
WO1999061042A1 (en) * 1998-05-28 1999-12-02 Vickery Brice E Compositions and methods for enhancing protein anabolism and detoxification
US6444234B1 (en) * 1998-07-07 2002-09-03 Kenneth B Kirby Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US20040247669A1 (en) * 2003-02-04 2004-12-09 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973605A (en) * 1979-08-30 1990-11-27 Herschler R J Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals
US4568547A (en) * 1979-08-30 1986-02-04 Herschler R J Solid pharmaceutical compositions comprising MSM and their production
US4559329A (en) * 1982-09-14 1985-12-17 Herschler R J Dietary and pharmaceutical uses of methyl-sulfonylmethane and compositions comprising it
US4447469A (en) * 1982-06-10 1984-05-08 Hughes Aircraft Company Process for forming sulfide layers by photochemical vapor deposition
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4883128A (en) * 1986-07-30 1989-11-28 Donald L. O'Neall Guidance system for farm implements
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5569679A (en) * 1994-12-30 1996-10-29 Russell A. Krueger Pharmaceuticals, Inc. Pharmacologic management of snoring
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5925377A (en) * 1997-08-07 1999-07-20 Nova Pharmaceutical Co. Dietary supplement composition
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6440391B1 (en) * 2000-06-02 2002-08-27 Elstan Corporation Management of snoring by oral administration of dimethyl sulfone
US6416772B1 (en) * 2001-01-12 2002-07-09 H. Wayne Van Engelen Topical dermal anaesthetic
US6541045B1 (en) * 2002-01-04 2003-04-01 Nutraceutical Corporation Herbal composition and method for combating inflammation
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
EP1592435A4 (en) * 2002-12-20 2008-01-23 Chakshu Res Inc EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
JP2007533686A (ja) * 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性的障害ｉｉ治療用の新規医薬組成物
US20050244502A1 (en) * 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
JP2006290792A (ja) * 2005-04-11 2006-10-26 Tm East:Kk 抗炎症剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005293A1 (en) * 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
WO1999061042A1 (en) * 1998-05-28 1999-12-02 Vickery Brice E Compositions and methods for enhancing protein anabolism and detoxification
US6444234B1 (en) * 1998-07-07 2002-09-03 Kenneth B Kirby Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US20040247669A1 (en) * 2003-02-04 2004-12-09 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104352461A (zh) * 2013-04-28 2015-02-18 南京海融医药科技有限公司 他达拉非的口服药物制剂
CN104352461B (zh) * 2013-04-28 2017-07-14 南京海融医药科技股份有限公司 他达拉非的口服药物制剂
CN111956652A (zh) * 2020-08-21 2020-11-20 重庆康刻尔制药股份有限公司 一种西地那非口腔膜剂药物组合及其制备方法

Also Published As

Publication number Publication date
KR20090125100A (ko) 2009-12-03
WO2008099397A2 (en) 2008-08-21
AU2008215771A1 (en) 2008-08-21
JP2010519196A (ja) 2010-06-03
WO2008099397A3 (en) 2010-01-07
ZA200905697B (en) 2010-10-27
CA2678500A1 (en) 2008-08-21
US20100086495A1 (en) 2010-04-08
EP2114384A2 (en) 2009-11-11
EP2114384A4 (en) 2012-02-01
BRPI0807943A2 (pt) 2014-10-21

Similar Documents

Publication Publication Date Title
CN101754755A (zh) 促进跨粘膜递送的组合物及方法
WO2014024193A1 (en) Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients
ES2380747T3 (es) Métodos y medicamentos para administración de ibuprofeno
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
JP5542309B2 (ja) 経口医薬組成物
WO2008134540A1 (en) Compositions and methods for transmucosal delivery of domperidone
TW201815393A (zh) Grapiprant組合物及其使用方法
US20220008342A1 (en) Combination tablet with chewable outer layer
US12246042B2 (en) Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
JP6258342B2 (ja) イブプロフェンナトリウム二水和物に基づく薬用トローチ
CN110475547A (zh) 治疗多发性硬化症的组合物和方法
US9155704B1 (en) More palatable, bioequivalent pharmaceutical composition of carprofen
HK1145630A (en) Compositions and methods for enhancing transmucosal delivery
JP2022066434A (ja) ロキソプロフェン又はその塩及びビタミンｅを含有する経口用医薬組成物
WO2023126970A1 (en) Oral films of non-steroidal anti-inflammatory drugs
JP5676834B2 (ja) 消化管への刺激性を減少した経口固形組成物
TR2023019306A2 (tr) Kerseti̇n, hi̇bi̇skus ekstresi̇, stevi̇a ve kafei̇n'i̇ bi̇r arada i̇çeren sporcular i̇çi̇n performans artirici oral i̇nce fi̇lm formülasyonlari
TR2023019244A1 (tr) Montelukast ve desloratadi̇n?i̇ bi̇r arada i̇çeren oral i̇nce fi̇lm formülasyonlari
WO2023126967A1 (en) Oral films of antipruritic drugs
WO2024144678A1 (en) Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms
WO2024144674A1 (en) Orally disintegrating (odt) tablets formulations containing indomethacin and famotidine
WO2024144656A1 (en) Orally disintegrating tablet (odt) formulations for osteoarthritis treatment
Ghadi et al. DESIGN AND EVALUATION OF NOVEL BI-LAYERED TABLET FOR THE EFFECTIVE TREATMENT OF HYPERTENSION
JP2020169151A (ja) ロキソプロフェン又はその塩とタウリンとを含有する経口医薬組成物
CN107157987A (zh) 含氮的天然产物的医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1145630

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100623

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1145630

Country of ref document: HK